AMG Detection is transforming epilepsy care with the first wearable device that predicts seizures before they happen—empowering millions of people living with epilepsy to live more safely and independently. Current solutions merely detect seizures after they start, often with high false-positive rates triggered by non-seizure activities. Our proprietary technology uses a breakthrough semiconductor-based VOC sensor to detect subtle chemical changes in sweat—providing a 10-45 minute warning window and even identifying seizure type. Backed by over a decade of research and a 95% accuracy rate in lab tests, our device bridges the gap between AI and biosensing, integrating seamlessly with vital-sign monitors to reduce injuries, enhance quality of life, and prevent SUDEP. We are partnering with top neurologists and regulatory experts to complete preclinical trials in leading epilepsy centers across the US and Europe. Our revenue model combines upfront device sales with recurring subscriptions for software updates and cloud-based analytics. With strategic collaborations and a strong IP portfolio, AMG Detection is positioned to revolutionize epilepsy care and set the standard for predictive health monitoring. We’re not just detecting seizures—we’re giving people their freedom back.